Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Home sapiens and Mus musculus

ABSTRACT: In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model

PROVIDER: PRJNA869109 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23571400_1.fastq.gz	Fastqsanger.gz
	SRR23571400_2.fastq.gz	Fastqsanger.gz
	SRR23572500_1.fastq.gz	Fastqsanger.gz
	SRR23572500_2.fastq.gz	Fastqsanger.gz
	SRR23571401_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 246

Similar Datasets

Homo sapiens

Project description:Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice

| PRJNA915048 | ENA

Homo sapiens

Project description:In vivo prime editing rescues alternating hemiplegia of childhood in mice

| PRJNA1211588 | ENA

Treatment of a metabolic liver disease by in vivo prime editing in mice

Project description:Prime editing is a highly versatile CRISPR-based genome editing technology with the potential to correct the vast majority of genetic defects1. However, correction of a disease phenotype in vivo in somatic tissues has not been achieved yet. Here, we establish proof-of-concept for in vivo prime editing, that resulted in rescue of a metabolic liver disease. We first develop a size-reduced prime editor (PE) lacking the RNaseH domain of the reverse transcriptase (SpCas9-PERnH), and a linker- and NLS-optimized intein-split PE construct (SpCas9-PE p.1153) for delivery by adeno-associated viruses (AAV). Systemic dual AAV-mediated delivery of this variant in neonatal mice enables installation of a transversion mutation at the Dnmt1 locus with 15% efficiency on average. Next, we targeted the disease-causing mutation in the phenylalanine hydroxylase (Pah)enu2 mouse model for phenylketonuria (PKU). Correction rates of 1.5% using the dual AAV approach could be increased to up to 14% by delivery of full-length SpCas9-PE via adenoviral vector 5 (AdV5), leading to full restoration of physiological blood phenylalanine (L-Phe) levels below 120 µmol/L. Our study demonstrates in vivo prime editing in the liver at two independent loci, emphasizing the potential of PEs for future therapeutic applications.

2021-12-29 | GSE174757 | GEO

Project description:In vivo Adenine Base Editing rescues adrenoleukodystrophy in a humanized mouse model

| PRJNA1020620 | ENA

Project description:Base editing of hematopoietic stem cells rescues sickle cell disease in mice

| PRJNA725249 | ENA

Project description:In vivo postnatal base editing rescues hearing in a mouse model of recessive deafness

| PRJNA578156 | ENA

Mouse, Human

Project description:A simplified, G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model

| PRJNA1101957 | ENA

Mus musculus

Project description:In vivo photoreceptor base editing rescues the rhodopsin-E150K autosomal-recessive retinitis-pigmentosa mouse model

| PRJNA1129541 | ENA

Prime editing for functional repair in patient-derived disease models

Project description:Prime editing is a novel genome editing technology using fusion proteins of Cas9-nickase and reverse transcriptase, that holds promise to correct a wide variety of genetic defects. We succeeded in efficient prime editing and functional recovery of disease-causing mutations in patient-derived liver and intestinal stem cell organoids. Whole genome sequencing of did not detect off-target mutations or a mutational signature induced by prime editing.

| EGAS00001004611 | EGA

Evaluating CRISPR-based Prime Editing for cancer modeling and CFTR repair in organoids

Project description:We evaluate CRISPR-based prime editing for application in organoids. First we model mutations in TP53 in intestinal and hepatocyte oganoids and determine the efficiency and accuracy of mutation induction on multiple targets. Then, to evaluate potential clinical applicability of prime editing we repair mutations in the CFTR channel that cause cystic fibrosis in intestinal organoids. First we repair the CFTR-F508del mutation which is the most common mutation in cystic fibrosis. Then we compare adenine base editing to prime editing by repairing the CFTR-R785* mutation using both strategies.

| EGAS00001005358 | EGA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data